Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Karyopharm Therapeutics Inc. (KPTI) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/02/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
08/02/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/02/2023 8-K Quarterly results
07/10/2023 SC 13G/A STATE STREET CORP reports a 1.9% stake in EXIT FILING KARYOPHARM THERAPEUTICS INC
05/25/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
05/08/2023 EFFECT Form EFFECT - Notice of Effectiveness:
05/04/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/04/2023 8-K Quarterly results
03/31/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
03/10/2023 8-K Regulation FD Disclosure  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549"
02/14/2023 SC 13G/A COMMODORE CAPITAL LP reports a 1.7% stake in Karyopharm Therapeutics, Inc.
02/14/2023 SC 13G/A Chione Ltd reports a 3.9% stake in Karyopharm Therapeutics Inc.
02/14/2023 SC 13G/A Avidity Partners Management LP reports a 9.9% stake in Karyopharm Therapeutics Inc.
02/02/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
01/20/2023 SC 13G BlackRock Inc. reports a 10.5% stake in KARYOPHARM THERAPEUTICS INC
01/09/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549",
"Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Revenue and Outlines 2023 Objectives"
12/23/2022 S-3 Form S-3 - Registration statement under Securities Act of 1933:
12/13/2022 8-K Other Events  Interactive Data
12/08/2022 D Form D - Notice of Exempt Offering of Securities:
12/08/2022 SC 13G Avidity Partners Management LP reports a 9.9% stake in Karyopharm Therapeutics Inc.
12/05/2022 8-K Quarterly results
12/02/2022 8-K Quarterly results
11/03/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/03/2022 8-K Quarterly results
08/04/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/04/2022 8-K Quarterly results
Docs: "Karyopharm Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress"
07/28/2022 8-K Quarterly results
06/15/2022 8-K Quarterly results
06/03/2022 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
05/23/2022 8-K Quarterly results
05/12/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
05/09/2022 SC 13G COMMODORE CAPITAL LP reports a 5.1% stake in Karyopharm Therapeutics Inc.
05/05/2022 10-Q Quarterly Report for the period ended March 31, 2022
05/05/2022 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy